1. No additional acute inpatient benefit
Short-term AT (10 days) during hospitalization did not provide added tinnitus improvement beyond standard steroid ± batroxobin therapy, although all groups improved over the inpatient period.

2. Long-term AT may benefit severe ISSHL (exploratory finding)
At 6 months, only patients with severe hearing loss showed significantly higher tinnitus remission with home-based AT (≈25-point absolute increase). This was an exploratory subgroup result and requires confirmation.

3. No clear long-term benefit in mild or moderate ISSHL
For patients with milder hearing thresholds, the study did not detect additional tinnitus improvement from long-term AT beyond the spontaneous recovery seen in all groups.

4. AT in this study involved individualized matching and sustained daily use
The AT protocol used customized tinnitus frequency/loudness matching plus 1.5–3 hours/day of structured use over months.

5. Treatment appeared safe
No serious AT-related adverse events occurred. Batroxobin produced expected coagulation-related effects, which were manageable with routine fibrinogen monitoring.